Genetic Analysis AS Stock Price

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Fecal Test, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples. It is also involved in the operation of service laboratory where customers can send samples for microbiome profiling analysis; and provision of bioinformatic analysis and custom panel services. The company was founded in 2008 and is headquartered in Oslo, Norway.